- Home
- Featured Publications
- Center Publications
- Sel1L-Hrd1 ER-associated degradation maintains β cell identity via TGF-β signaling.
Sel1L-Hrd1 ER-associated degradation maintains β cell identity via TGF-β signaling.
Citation | “Sel1L-Hrd1 Er-Associated Degradation Maintains Β Cell Identity Via Tgf-Β Signaling.”. The Journal Of Clinical Investigation, pp. 3499-3510. . |
Center | University of Michigan |
Author | Neha Shrestha, Tongyu Liu, Yewei Ji, Rachel B Reinert, Mauricio Torres, Xin Li, Maria Zhang, Chih-Hang Anthony Tang, Chih-Chi Andrew Hu, Chengyang Liu, Ali Naji, Ming Liu, Jiandie D Lin, Sander Kersten, Peter Arvan, Ling Qi |
Keywords | beta cells, Cell Biology, diabetes, Metabolism, Protein misfolding |
Abstract |
β Cell apoptosis and dedifferentiation are 2 hotly debated mechanisms underlying β cell loss in type 2 diabetes; however, the molecular drivers underlying such events remain largely unclear. Here, we performed a side-by-side comparison of mice carrying β cell-specific deletion of ER-associated degradation (ERAD) and autophagy. We reported that, while autophagy was necessary for β cell survival, the highly conserved Sel1L-Hrd1 ERAD protein complex was required for the maintenance of β cell maturation and identity. Using single-cell RNA-Seq, we demonstrated that Sel1L deficiency was not associated with β cell loss, but rather loss of β cell identity. Sel1L-Hrd1 ERAD controlled β cell identity via TGF-β signaling, in part by mediating the degradation of TGF-β receptor 1. Inhibition of TGF-β signaling in Sel1L-deficient β cells augmented the expression of β cell maturation markers and increased the total insulin content. Our data revealed distinct pathogenic effects of 2 major proteolytic pathways in β cells, providing a framework for therapies targeting distinct mechanisms of protein quality control. |
Year of Publication |
2020
|
Journal |
The Journal of clinical investigation
|
Volume |
130
|
Issue |
7
|
Number of Pages |
3499-3510
|
Date Published |
07/2020
|
ISSN Number |
1558-8238
|
DOI |
10.1172/JCI134874
|
Alternate Journal |
J. Clin. Invest.
|
PMID |
32182217
|
PMCID |
PMC7324191
|
Download citation |